无常规可调控危险因素冠状动脉粥样硬化患者的临床路径
该综述指出,尽管无标准可调控心血管危险因素(SMuRF)者仍可发生冠状动脉粥样硬化,且此类心肌梗死患者早期死亡率意外更高,但缺乏循证管理证据。作者组建国际多学科团队,采用改良德尔菲法制定临床路径,旨在确认动脉粥样硬化与真正无SMuRF状态、确保循证二级预防并考虑非典型贡献因素的额外检查。
要点
- 无SMuRF的CAD患者仍存在,且心梗后早期死亡率高于至少有1个SMuRF者。
- 该路径采用改良德尔菲法制定,强调确认动脉粥样硬化与真正无SMuRF状态。
- 路径确保循证二级预防,并考虑非典型贡献因素的额外检查与干预。
核心结论
- 针对无SMuRF的CAD患者,国际多学科团队制定了循证临床路径,旨在通过加强二级预防依从性和额外诊断可调控危险因素来改善结局。
研究设计与样本
- 综述类:国际多学科团队采用改良德尔菲法制定临床路径,并计划配套注册研究。
主要发现
- 无SMuRF的CAD患者数量可观,其心肌梗死早期死亡率意外高于至少有1个SMuRF者。
- 针对该人群的最佳管理证据缺乏。
关键数值与推荐
- 路径确认 underlying atherosclerosis 和 true SMuRFless 状态,确保 evidence-based secondary prevention,并考虑 less typical contributors 的额外 tests and interventions。
临床怎么用
- 临床应识别无SMuRF但存在冠状动脉粥样硬化的患者,按路径确认诊断并强化循证二级预防。
- 对非典型贡献因素考虑额外检查与干预,并通过注册研究追踪结局。
局限性
- 原文未报告路径的具体推荐条款、数值阈值或证据等级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors (SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD). However, a substantial number of individuals develop coronary atherosclerosis despite no SMuRFs. SMuRFless patients presenting with myocardial infarction have been observed to have an unexpected higher early mortality compared to their counterparts with at least 1 SMuRF. Evidence for optimal management of these patients is lacking. We assembled an international, multidisciplinary team to develop an evidence-based clinical pathway for SMuRFless CAD patients. A modified Delphi method was applied. The resulting pathway confirms underlying atherosclerosis and true SMuRFless status, ensures evidence-based secondary prevention, and considers additional tests and interventions for less typical contributors. This dedicated pathway for a previously overlooked CAD population, with an accompanying registry, aims to improve outcomes through enhanced adherence to evidence-based secondary prevention and additional diagnosis of modifiable risk factors observed.
引用
- Figtree GA, Vernon ST, Harmer JA, et al. Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023. PMID: 37730292. doi:10.1016/j.jacc.2023.06.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。